Maia Biotechnology Inc (MAIA) Stock Price, Quote & News

Company Profile

MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Industry: Biotechnology

Sector: Healthcare

Phone: 312-416-8592

Website: maiabiotech.com

Address:

444 West Lake Street, Suite 1700, Chicago, United States

LabPsycho Oct. 7 at 11:59 PM

$MAIA The management of several biotech companies doing similar multilevel Ponzi Scheme^2 (fiat random digital number backed by fiat USD currency) don't seem to even care anymore that they have been exposed as grifters - its just business as usual, their greed has no limits when their moral compasses are gone. Such insanity (biotechs switchin to doing digital whatevers and low floats like SPRB going from 7 to 250 in hours) may be a harbinger of a peak coming soon in the overall market followed by a serious correction....maybe 2 months.

0 · Reply

MoneyHelix Oct. 7 at 10:40 PM

$MAIA 2.4M shares traded on stupid ass crypto news shows how dumb the markets are right now. Wayyyy too much capital is being dumped into crypto BS. However, this strategy might actually work because of dumb luck on crypto appreciation. I'm holding until I see what percentage of their capital they put into crypto and the first data readout of Phase 2C. The speculative nature of the crypto markets and positive data could, ironically, push this stock up significantly.

0 · Reply

Kumakei Oct. 7 at 10:39 PM

$MAIA just mention you are getting into HPC, so that we can rocket

1 · Reply

GISBlaster98 Oct. 7 at 7:58 PM

$MAIA Sure hope the next Press Release is scientific in nature or I am going to start to reduce my holdings…

2 · Reply

FerrariF12Lover Oct. 7 at 7:45 PM

$MAIA Digital asset news

0 · Reply

MoneyHelix Oct. 7 at 7:12 PM

$MAIA MAIA should make an NFT of the chemical structure of Ateganosine 🤣 because why the fuck not at this point

1 · Reply

FreedomQuestTrader Oct. 7 at 6:10 PM

$MAIA nice 16% scalp in the free section of the server.

0 · Reply

telomerase Oct. 7 at 4:43 PM

$MAIA pretty funny that investors aren't interested in "we've tripled OS in NSCLC", but "we're the 597th crypto speculation company" has them jumping right in ;)

1 · Reply

mostlyzero Oct. 7 at 3:25 PM

$MAIA I hear what you all are saying and my traditionalist streak tells me I should just liquidate and move on. But my Wall Street bets 💎 🙌 - yolo streak tells me I should load up for the pump… and then dump. If news like this gets out and gets traction in certain corridors, the 2000 watchers here could turn into 10,000 and this thing could shoot up. Stranger things have happened. Definitely 1000% not investment advice.

1 · Reply

LabPsycho Oct. 7 at 2:15 PM

$MAIA Did I not call out how suspect the management of this company was over a year ago?! The head fake insider buying, the over the top confidence in their oral presentations - lots of red flags obvious long ago. But hey nothing says our drugs dont work and this was all a big con from the beginning like a biotech switching to digital currency - many beat down biotechs have jumped on this scam du jour recently. The multi-layer Ponzi scheme and wealth transfer from you to them continues

2 · Reply

MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets

Sep 29, 2025, 4:30 PM EDT - 8 days ago

MAIA Biotechnology Announces $2.25 Million Private Placement

Sep 24, 2025, 8:01 AM EDT - 13 days ago

MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent

Sep 5, 2025, 9:03 AM EDT - 4 weeks ago

MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer

Aug 27, 2025, 9:01 AM EDT - 5 weeks ago

MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells

Aug 18, 2025, 8:00 AM EDT - 7 weeks ago

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

Jul 28, 2025, 8:01 AM EDT - 2 months ago

MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer

Jul 17, 2025, 9:17 AM EDT - 2 months ago

MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy

Jul 9, 2025, 9:15 AM EDT - 3 months ago

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

Jul 1, 2025, 9:00 AM EDT - 3 months ago

MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

Jun 24, 2025, 8:15 AM EDT - 3 months ago

MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

Jun 18, 2025, 9:15 AM EDT - 3 months ago

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

Jun 10, 2025, 8:46 AM EDT - 4 months ago

MAIA Biotechnology to Present at BIO International Convention 2025

Jun 5, 2025, 2:28 PM EDT - 4 months ago

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

Jun 5, 2025, 11:10 AM EDT - 4 months ago

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

Jun 5, 2025, 8:04 AM EDT - 4 months ago

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer

May 27, 2025, 5:35 PM EDT - 4 months ago

CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000

May 27, 2025, 4:30 PM EDT - 4 months ago

MAIA Biotechnology Announces Private Placement of Approximately $669,500

May 15, 2025, 11:05 AM EDT - 5 months ago

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 14, 2025, 10:15 AM EDT - 5 months ago

MAIA Biotechnology Announces Director Participation in Recent Private Placement

May 5, 2025, 11:45 PM EDT - 5 months ago

CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement

May 5, 2025, 4:05 PM EDT - 5 months ago

MAIA Biotechnology Announces $1.08 Million Private Placement

Apr 1, 2025, 8:30 AM EDT - 6 months ago

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

Mar 25, 2025, 8:46 AM EDT - 7 months ago

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

Mar 20, 2025, 9:20 AM EDT - 7 months ago

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

Mar 19, 2025, 11:00 AM EDT - 7 months ago

MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO

Feb 27, 2025, 8:51 AM EST - 7 months ago

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

Feb 26, 2025, 8:47 AM EST - 7 months ago

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

Feb 24, 2025, 4:30 PM EST - 8 months ago

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

Feb 18, 2025, 3:44 PM EST - 8 months ago

MAIA Biotechnology Announces Private Placement of $2,715,000

Feb 4, 2025, 8:51 AM EST - 8 months ago

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

Jan 10, 2025, 9:45 AM EST - 9 months ago

MAIA Biotechnology to Present at Biotech Showcase 2025

Dec 19, 2024, 8:47 AM EST - 10 months ago

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

Dec 16, 2024, 8:37 AM EST - 10 months ago

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

Dec 9, 2024, 6:00 PM EST - 10 months ago

MAIA Biotechnology Announces Private Placement of Approximately $950,000

Dec 3, 2024, 8:17 AM EST - 11 months ago

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

Nov 7, 2024, 8:47 AM EST - 11 months ago

MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

Nov 5, 2024, 9:45 AM EST - 1 year ago

MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 28, 2024, 7:00 PM EDT - 1 year ago

MAIA Biotechnology Announces $2.44 Million Private Placement

Oct 15, 2024, 8:15 AM EDT - 1 year ago

MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics

Sep 10, 2024, 6:00 AM EDT - 1 year ago

MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer

Sep 4, 2024, 8:30 AM EDT - 1 year ago

MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

Jul 23, 2024, 10:38 AM EDT - 1 year ago

MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients

Jul 23, 2024, 4:11 AM EDT - 1 year ago

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

Jun 7, 2024, 12:31 PM EDT - 1 year ago

MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy

Jun 6, 2024, 10:07 AM EDT - 1 year ago

MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent

Jun 4, 2024, 8:41 AM EDT - 1 year ago

MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer

May 17, 2024, 8:37 AM EDT - 1 year ago

MAIA Biotechnology to Present at the BIO International Convention 2024

May 16, 2024, 8:37 AM EDT - 1 year ago

MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Apr 30, 2024, 8:08 AM EDT - 1 year ago

MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement

LabPsycho Oct. 7 at 11:59 PM

0 · Reply

MoneyHelix Oct. 7 at 10:40 PM

0 · Reply

Kumakei Oct. 7 at 10:39 PM

$MAIA just mention you are getting into HPC, so that we can rocket

1 · Reply

GISBlaster98 Oct. 7 at 7:58 PM

$MAIA Sure hope the next Press Release is scientific in nature or I am going to start to reduce my holdings…

2 · Reply

FerrariF12Lover Oct. 7 at 7:45 PM

$MAIA Digital asset news

0 · Reply

MoneyHelix Oct. 7 at 7:12 PM

$MAIA MAIA should make an NFT of the chemical structure of Ateganosine 🤣 because why the fuck not at this point

1 · Reply

FreedomQuestTrader Oct. 7 at 6:10 PM

$MAIA nice 16% scalp in the free section of the server.

0 · Reply

telomerase Oct. 7 at 4:43 PM

$MAIA pretty funny that investors aren't interested in "we've tripled OS in NSCLC", but "we're the 597th crypto speculation company" has them jumping right in ;)

1 · Reply

mostlyzero Oct. 7 at 3:25 PM

1 · Reply

LabPsycho Oct. 7 at 2:15 PM

2 · Reply

DiamondDog33 Oct. 7 at 2:15 PM

$MAIA basically saying the Cancer programs are "dead" in the water ....PROBLEM has always been CASH.. and it tells you they cannot raise any ..... Are the principles just HOPING!!! to get their money back they put into all those Warrants ...LMAO LMAO LMAO !!!!!! Buy Target for me is like 50cents ... 90 pct of their poultry 5-10 mil ???? the rest ADMIN CASH NO MONEY for the trials

1 · Reply

ReturnOfEsquire Oct. 7 at 2:05 PM

$MAIA Glad I sold for a small gain years ago. Management is an unserious group of people. If shareholders wanted their money invested in Bitcoin, they could have done so themselves.

1 · Reply

jcmeredith1 Oct. 7 at 2:03 PM

$MAIA when Bitcoin is sitting at $150K in January and MAIA raises the next tranche at $2.25 instead of $1.5 this move will look pretty good.

1 · Reply

DiamondDog33 Oct. 7 at 1:57 PM

$MAIA 90 pct ???????????????????????of the liquid reserves into Bit/Ethe .......THEY ONLY HAVE LIKE 5-10 MILLION ....LOL LOL LOL LOL LOL WHAT THIS TELLS YOU IS .........THERE WILL BE NO MAJOR TRIALS AND CERTAINLY NOT GOING TO BE ANY APPROVALS ANYTIME <<<<<<<<<<<<<<<<<< They know they cant get any CASH .....so instead of just MERGING with a COMPANY to take PROGRAMS forward.. PRINCIPLES are hoping to one day get their cash back in crypto .. LOL LOL total GAMBLE .... and NO CHANCE AT CANCER APPROVALS ...A JOKE!!!!!!!!!!!!!!!!!! Figured out the PROMO CO.....

1 · Reply

Kremm Oct. 7 at 1:57 PM

$MAIA yeah that's it for me - management lost their marbles

0 · Reply

PremarketAnalysis Oct. 7 at 1:55 PM

$MAIA showing reversal attempt after prior breakdown confirmation.. buyers stepping in near 1.77 but needs reclaim over 1.93 for sustained upside Momentum Feed: https://premarketanalysis.com/#momentum=MAIA

0 · Reply

MoneyHelix Oct. 7 at 1:24 PM

$MAIA This announcement is incredibly weird

2 · Reply

AlextheDubs Oct. 7 at 1:17 PM

$MAIA I would think it’s crazy to trade existing shareholder cash for bitcoins……however if they are raising funds by taking digital currency (from who knows what type of investors) instead of cash perhaps that allows for cash conversion downstream when it’s needed for trials with the upside of digital appreciation….but youd be playing with the casinos and if this works , there is upside and cash runway without the massive dilution of traditional equity offerings. They will need to explain ….and also start building a legit IR department.

0 · Reply

strategicmind Oct. 7 at 1:08 PM

$MAIA up to 90% what a bad idea. That’s wayyyy too high. They need money , they don’t have any and they are going to gamble for it??!

2 · Reply

Laurapicksright Oct. 7 at 1:06 PM

$MAIA Massive treasury news 😍😍 Watching $GME $OPEN $TSLA $BBAI

0 · Reply

Laurapicksright Oct. 7 at 1:04 PM

$MAIA MAIA Biotechnology Authorizes Up To 90% Of Liquid Assets In Bitcoin, Ethereum, And USD Coin For New Digital Treasury Strategy #tradeideas Watching $AMD $TSLA $BURU $INTC

0 · Reply

DARKP00L Oct. 7 at 1:02 PM

$MAIA 08:49 on Oct. 07 2025 MAIA Biotechnology Authorizes Up To 90% Of Liquid Assets In Bitcoin, Ethereum, And USD Coin For New Digital Treasury Strategy #tradeideas

0 · Reply

Market Cap	57.08M
Revenue (ttm)	0.00
Net Income (ttm)	-23.25M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,390,700
Avg Vol	445,656
Day's Range	N/A - N/A
Shares Out	32.99M
Stochastic %K	59%
Beta	0.01
Analysts	Sell
Price Target	$14.00